TransMedics Group (TMDX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $108.8 million, up 64% year-over-year, driven by increased OCS utilization and logistics services, but down 5% sequentially due to lower U.S. transplant volumes and scheduled aircraft maintenance.

• Net income was $4.2 million ($0.12 per diluted share) in Q3 2024, reversing a net loss of $25.4 million in Q3 2023.

• Gross margin declined to 56% from 61% in Q2 2024 and Q3 2023, mainly due to infrastructure investments, higher service revenue mix, and increased use of third-party logistics.

• U.S. revenue grew 76% year-over-year, while OUS revenue declined 40% year-over-year and 45% sequentially, reflecting expected variability and lack of broad reimbursement.

• Market share and center penetration for heart, lung, and liver remained stable despite national volume declines.

Financial highlights

• Product revenue was $65.9 million; service revenue was $42.9 million (39.4% of total), both up significantly year-over-year.

• Product margin reached 80%, up from 77% in Q3 2023; service margin was 19%, impacted by non-recurring costs and reliance on third-party logistics.

• Operating expenses totaled $56.9 million, down from $69.0 million in Q3 2023 due to absence of prior year $27.2 million acquired IPR&D expense.

• Cash balance at quarter-end was $330.1 million, down from $362.8 million at the end of Q2, reflecting $42 million in aircraft purchases.

• Earnings per share was $0.13 (basic), $0.12 (diluted).

Outlook and guidance

• Full-year 2024 revenue guidance maintained at $425–$445 million, representing 76–84% growth over 2023.

• Management expects margin variability to persist in the near term due to ongoing investments but anticipates improvement as scale and operational efficiencies increase.

• Early Q4 trends indicate normalization of transplant volumes, supporting confidence in guidance.

• Long-term gross margin target remains in the mid-60% range, dependent on increased use of owned aircraft and service efficiency.

• Existing cash is expected to fund operations, capex, and debt service for at least 12 months.